Klarna, a leading global retail bank has signed an agreement to acquire PriceRunner. PriceRunner is a leading comparison shopping service in the Nordic region.

The company has more than 170 employees, businesses in Sweden, Denmark, Norway and the United Kingdom and compares 3.4 million products from 22,500 retailers in 25 countries. During the 12-month period ending on Sep 30, 2021, PriceRunner had revenues amounting to MSEK 460. PriceRunner will bring new features in the form of product reviews, rich product discovery and price comparisons to the Klarna app to enhance the shopping, payments and banking experience for consumers globally.

The transaction is subject to customary regulatory approvals.

Vinge’s team primarily consisted of Johan Larsson, Samra Baytar, Stina Bengtsson, Clara Sohlberg and Robin Fagerström (M&A), Sebastian Örndahl and Johan Wahlbom (Competition), Emma Stuart Beck and Henrik Schön (Financial Regulatory), Cecilia Möller Norsted and Anna-Karin Alin (Litigation), Martin Boström, Lisa Hörnqvist and Karl-Hugo Engdahl (IT/GDPR), Klara Secher and Rebecka Målquist (IP), Isabell Nielsen and Mario Saad (Commercial Agreements), Kamyar Najmi and Benjamin Vafaeian (Banking & Financing), Gustav Lindgren (Employment) and Tove Lövgren Frisk (Compliance).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026